FDA Inspection 1298628 — Eli Lilly & Company

Eli Lilly & Company — FEI 1819470

The FDA completed an inspection of Eli Lilly & Company on Jan 9, 2026 in Indianapolis, IN. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Jan 9, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Indianapolis, IN (United States)

Additional Details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.